Literature DB >> 15659568

Cytochrome P450 1A1 and 1B1 in human blood lymphocytes are not suitable as biomarkers of exposure to dioxin-like compounds: polymorphisms and interindividual variation in expression and inducibility.

Majorie B M van Duursen1, J Thomas Sanderson, Martin van den Berg.   

Abstract

Cytochrome P450 1A1 (CYP1A1) and 1B1 (CYP1B1) are phase I enzymes, the expression of which can be affected by many environmental compounds, including dioxins and dioxin-like compounds. Because CYP1A1 and CYP1B1 expression can easily be determined in peripheral blood lymphocytes, it is often suggested as biomarker of exposure to these compounds. In this study we investigated the interindividual differences in constitutive and induced CYP1A1-catalyzed ethoxyresorufin-O-deethylase (EROD) activity and CYP1A1 and CYP1B1 gene expression in human blood lymphocytes in a group of ten non-smoking females. Freshly isolated lymphocytes were cultured in medium containing the mitogen PHA and were exposed to the most potent dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or the less potent dioxin-like polychlorinated biphenyl 126 (PCB126). In addition, we determined the occurrence of the CYP1A1 MspI and CYP1B1 Leu432Val polymorphisms. All individuals showed a concentration-dependent increase of EROD activity by TCDD, which was significantly correlated with an increase in CYP1A1, but not CYP1B1 expression. The maximum induced EROD activity by TCDD was very different among the individuals, but the EC50 values were about the same. PCB126 also caused a concentration-dependent increase of EROD activity, but was a factor 100-1000 less potent than TCDD among the individuals. The allele frequencies for CYP1A1 MspI and CYP1B1 Leu432Val reflected a normal Caucasian population and in this study the polymorphisms had no apparent effect on the expression and activity of these enzymes. Our study shows a large interindividual variability in constitutive and induced EROD activity, and CYP1A1 and CYP1B1 expression in human lymphocytes. In addition, dioxin concentrations at which effects were observed in our in vitro study are about 10-fold higher than the human blood levels found in vivo, indicating that EROD activity and CYP1A1 and CYP1B1 expression in human lymphocytes might not be applicable as biomarkers of exposure to dioxin and dioxin-like compounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15659568     DOI: 10.1093/toxsci/kfi089

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  12 in total

1.  Ahr and Cyp1a2 genotypes both affect susceptibility to motor deficits following gestational and lactational exposure to polychlorinated biphenyls.

Authors:  Breann T Colter; Helen Frances Garber; Sheila M Fleming; Jocelyn Phillips Fowler; Gregory D Harding; Molly Kromme Hooven; Amy Ashworth Howes; Smitha Krishnan Infante; Anna L Lang; Melinda Curran MacDougall; Melinda Stegman; Kelsey Rae Taylor; Christine Perdan Curran
Journal:  Neurotoxicology       Date:  2018-03       Impact factor: 4.294

2.  Relative effect potency estimates of dioxin-like activity for dioxins, furans, and dioxin-like PCBs in adults based on cytochrome P450 1A1 and 1B1 gene expression in blood.

Authors:  Soňa Wimmerová; Martin van den Berg; Jana Chovancová; Henrieta Patayová; Todd A Jusko; Majorie B M van Duursen; Ľubica Palkovičová Murínová; Rocio F Canton; Karin I van Ede; Tomáš Trnovec
Journal:  Environ Int       Date:  2016-08-31       Impact factor: 9.621

3.  Genetic variation in the CYP1A1 gene is related to circulating PCB118 levels in a population-based sample.

Authors:  Lars Lind; Johanna Penell; Anne-Christine Syvänen; Tomas Axelsson; Erik Ingelsson; Andrew P Morris; Cecilia Lindgren; Samira Salihovic; Bert van Bavel; P Monica Lind
Journal:  Environ Res       Date:  2014-06-11       Impact factor: 6.498

4.  Cyp1B1 mRNA expression in correlation to cotinine levels with respect to the Cyp1B1 L432V gene polymorphism.

Authors:  Simone Helmig; Jens Udo Seelinger; Monika Philipp-Gehlhaar; Juliane Döhrel; Joachim Schneider
Journal:  Eur J Epidemiol       Date:  2010-09-10       Impact factor: 8.082

5.  Human T lymphocytes bioactivate heterocyclic aromatic amines by forming DNA adducts.

Authors:  Medjda Bellamri; Ludovic Le Hegarat; Laurent Vernhet; Georges Baffet; Robert J Turesky; Sophie Langouët
Journal:  Environ Mol Mutagen       Date:  2016-11-01       Impact factor: 3.216

6.  Evidence of Association of CYP1A1 Expression in Blood Lymphocytes and Clinicopathological Variables in Oral Cancer.

Authors:  R D Singh; K A Patel; J B Patel; S J Pandya; P S Patel
Journal:  Indian J Clin Biochem       Date:  2021-02-12

7.  Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma.

Authors:  Laura S Gold; Anneclaire J De Roos; Elizabeth E Brown; Qing Lan; Kevin Milliken; Scott Davis; Stephen J Chanock; Yawei Zhang; Richard Severson; Sheila H Zahm; Tongzhang Zheng; Nat Rothman; Dalsu Baris
Journal:  Cancer Epidemiol       Date:  2009-09-06       Impact factor: 2.984

8.  Ahrd Cyp1a2(-/-) mice show increased susceptibility to PCB-induced developmental neurotoxicity.

Authors:  Christine Perdan Curran; Emily Altenhofen; Amy Ashworth; Austin Brown; Cellestine Kamau-Cheggeh; Melinda Curran; Amber Evans; Rikki Floyd; Jocelyn Fowler; Helen Garber; Breann Hays; Sarah Kraemer; Anna Lang; Andrea Mynhier; Ashton Samuels; Carly Strohmaier
Journal:  Neurotoxicology       Date:  2012-08-23       Impact factor: 4.294

9.  Impact of polychlorinated biphenyls contamination on estrogenic activity in human male serum.

Authors:  Martina Plísková; Jan Vondrácek; Rocio Fernandez Canton; Jirí Nera; Anton Kocan; Ján Petrík; Tomás Trnovec; Thomas Sanderson; Martin van den Berg; Miroslav Machala
Journal:  Environ Health Perspect       Date:  2005-10       Impact factor: 9.031

10.  Effects of in vitro brevetoxin exposure on apoptosis and cellular metabolism in a leukemic T cell line (Jurkat).

Authors:  Catherine J Walsh; Stephanie R Leggett; Kathryn Strohbehn; Richard H Pierce; John W Sleasman
Journal:  Mar Drugs       Date:  2008-06-10       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.